Delgoffe GM - Search Results

1

Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity.

Vignali PDA, DePeaux K, Watson MJ, Ye C, Ford BR, Lontos K, McGaa NK, Scharping NE, Menk AV, Robson SC, Poholek AC, Rivadeneira DB, Delgoffe GM. Vignali PDA, et al. Among authors: delgoffe gm. Nat Immunol. 2023 Feb;24(2):267-279. doi: 10.1038/s41590-022-01379-9. Epub 2022 Dec 21. Nat Immunol. 2023. PMID: 36543958 Free PMC article.

2

Exploring functional in vivo consequences of the selective genetic ablation of mTOR signaling in T helper lymphocytes.

Delgoffe GM, Powell JD. Delgoffe GM, et al. Methods Mol Biol. 2012;821:317-27. doi: 10.1007/978-1-61779-430-8_20. Methods Mol Biol. 2012. PMID: 22125075 Free PMC article.

3

The role of exhaustion in CAR T cell therapy.

Delgoffe GM, Xu C, Mackall CL, Green MR, Gottschalk S, Speiser DE, Zehn D, Beavis PA. Delgoffe GM, et al. Cancer Cell. 2021 Jul 12;39(7):885-888. doi: 10.1016/j.ccell.2021.06.012. Cancer Cell. 2021. PMID: 34256903 Free article.

4

The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation.

Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X. Gulen MF, et al. Among authors: delgoffe gm. Immunity. 2010 Jan 29;32(1):54-66. doi: 10.1016/j.immuni.2009.12.003. Epub 2010 Jan 7. Immunity. 2010. PMID: 20060329 Free PMC article.

5

Identity crisis: it's not just Foxp3 anymore.

Delgoffe GM, Bettini ML, Vignali DA. Delgoffe GM, et al. Immunity. 2012 Nov 16;37(5):759-61. doi: 10.1016/j.immuni.2012.10.012. Immunity. 2012. PMID: 23159220 Free PMC article.

6

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.

Powell JD, Delgoffe GM. Powell JD, et al. Among authors: delgoffe gm. Immunity. 2010 Sep 24;33(3):301-11. doi: 10.1016/j.immuni.2010.09.002. Immunity. 2010. PMID: 20870173 Free PMC article. Review.

7

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. Delgoffe GM, et al. Immunity. 2009 Jun 19;30(6):832-44. doi: 10.1016/j.immuni.2009.04.014. Immunity. 2009. PMID: 19538929 Free PMC article.

8

mTORC1 and mTORC2 selectively regulate CD8⁺ T cell differentiation.

Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, Delgoffe GM, Powell JD. Pollizzi KN, et al. Among authors: delgoffe gm. J Clin Invest. 2015 May;125(5):2090-108. doi: 10.1172/JCI77746. Epub 2015 Apr 20. J Clin Invest. 2015. PMID: 25893604 Free PMC article.

9

Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.

Fogli LK, Aurigemma R, Sommers CL, Singh A, Bourcier K, Ernstoff MS; NCI Cell Therapy Workshop Committee. Fogli LK, et al. J Immunother Cancer. 2021 Jul;9(7):e003048. doi: 10.1136/jitc-2021-003048. J Immunother Cancer. 2021. PMID: 34266886 Free PMC article.

10

PP2A's restraint of mTOR is critical for T(reg) cell activity.

Delgoffe GM. Delgoffe GM. Nat Immunol. 2016 May;17(5):478-9. doi: 10.1038/ni.3442. Nat Immunol. 2016. PMID: 27092798 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page